单克隆抗体药物研究进展recentadvancesinmonoclonal-药学学报.pdf

药学学报 Acta Pharmaceutica Sinica 20 17, 52 (6): 837 847 ·837 · ·综述· 单克隆抗体药物研究进展 赵晨曦, 胡卓伟, 崔 冰* ( 中国医学科学院、北京协和医学院 物研究所, 天然药物活性物质与功能国家重点实验室, 北京 100050) 摘要: 在过去40 多年, 单克隆抗体逐渐从单纯的科研工具 (试剂) 转变为强大的生物 用于多种疾病治疗。 迄今, 已有50 多种治疗性单克隆抗体经FDA 获准上市, 广泛用于肿瘤、自身免疫和感染等疾病的治疗。本文通 过抗体研究技术以及靶向肿瘤和免疫等相关 子进展, 综述单克隆抗体在临床疾病的诊断和治疗中的重要作用。 关键词: 生物制剂; 单克隆抗体; 抗体偶联药物; 免疫治疗; 免疫节点 中图分类号: R965 文献标识码: A 文章编号: 0513-4870 (20 17) 06-0837-11 Recent advances in monoclonal antibody-based therapeutics * ZHAO Chen-xi, HU Zhuo-wei, CUI Bing (State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Ac ademy of Medical Sciences and Peking Union Medical College, Beijing 100050, China ) Abstract : Over the past four decades, monoclonal antibodies (MAbs) have evolved from bioscience research tools to powerful biopharmaceutical MAbs products for multiple diseases treatment. More than 50 therapeutic MAbs have been approved by FDA, widely used in cancer, autoimmune diseases and other diseases in current market. This article reviews the current progress of MAbs development technology, key molecules for cancer- targeted therapy and immunotherapy, and emphasizes the importance of MAbs for disease diagnosis and treatment. Key words: biologics; monoclonal antibody; antibody-drug conju gate; immunotherapy; immune checkpoint 抗体是一种由效应 B 细胞分泌的免疫球蛋白, 1 单克隆抗体的技术进展 协助免疫系统鉴别、中和抗原或其他外来物质。抗 自然界中有机体通过多克隆免疫应答对抗抗原。 体由对称的 2 条重链及 2 条轻链组成,